Literature DB >> 24384910

Combining drugs and biologics to treat nasopharyngeal cancer.

Helen E Heslop1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24384910      PMCID: PMC3978800          DOI: 10.1038/mt.2013.272

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  16 in total

1.  Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.

Authors:  Corey Smith; Janice Tsang; Leone Beagley; Daniel Chua; Victor Lee; Vivian Li; Denis J Moss; William Coman; Kwok H Chan; John Nicholls; Dora Kwong; Rajiv Khanna
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  Perspective: assembly line immunotherapy.

Authors:  Bruce L Levine; Carl H June
Journal:  Nature       Date:  2013-06-27       Impact factor: 49.962

Review 3.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

4.  Getting personal with melanoma.

Authors:  Helen Heslop
Journal:  Clin Cancer Res       Date:  2011-06-28       Impact factor: 12.531

5.  Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

Authors:  Chrystal U Louis; Karin Straathof; Catherine M Bollard; Sravya Ennamuri; Claudia Gerken; Teresita T Lopez; M Helen Huls; Andrea Sheehan; Meng-Fen Wu; Hao Liu; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

Review 6.  Epstein-Barr virus: 40 years on.

Authors:  Lawrence S Young; Alan B Rickinson
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

7.  Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy.

Authors:  Debora Martorelli; Karim Houali; Laura Caggiari; Emanuela Vaccher; Luigi Barzan; Giovanni Franchin; Annunziata Gloghini; Alessandro Pavan; Alessandro Da Ponte; Rosa Maria Tedeschi; Valli De Re; Antonino Carbone; Tadamasa Ooka; Paolo De Paoli; Riccardo Dolcetti
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

8.  Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.

Authors:  Karin C M Straathof; Catherine M Bollard; Uday Popat; M Helen Huls; Teresita Lopez; M Craig Morriss; Mary V Gresik; Adrian P Gee; Heidi V Russell; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2004-11-12       Impact factor: 22.113

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.

Authors:  Whay-Kuang Chia; Marissa Teo; Who-Whong Wang; Bernett Lee; Soo-Fan Ang; Wai-Meng Tai; Chit-Lai Chee; Joanna Ng; Rebecca Kan; Wan-Teck Lim; Sze-Huey Tan; Whee-Sze Ong; Yin-Bun Cheung; Eng-Huat Tan; John E Connolly; Stephen Gottschalk; Han-Chong Toh
Journal:  Mol Ther       Date:  2013-10-17       Impact factor: 11.454

View more
  3 in total

Review 1.  Gene-modified cells for stem cell transplantation and cancer therapy.

Authors:  Malcolm K Brenner
Journal:  Hum Gene Ther       Date:  2014-07       Impact factor: 5.695

Review 2.  Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.

Authors:  Margaret L Gulley
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

3.  Curcumin loaded sub-30 nm targeting therapeutic lipid nanoparticles for synergistically blocking nasopharyngeal cancer growth and metastasis.

Authors:  Haiming Luo; Lisen Lu; Ni Liu; Qingqing Li; Xiaoquan Yang; Zhihong Zhang
Journal:  J Nanobiotechnology       Date:  2021-07-28       Impact factor: 10.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.